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Introduction: OSAS (Obstructive Sleep apnea syndrome) is defined by recurrent episodes of 
upper airway obstruction during sleep, causing multiple clinical consequences. Literature 
review suggests that OSAS induces a spectrum of abnormalities in neural, hormonal and 
vascular regulation that contribute to the development of ED (erectile dysfunction). 
The aims of this study were to estimate the prevalence of ED in OSAS patients and evaluate 
its determinants. 
Methods: 62 patients from Sleep Laboratory of Hospital S. João with newly diagnosed OSAS 
were included in the study and answered the IIEF-5 (international index erectile function 5 
item version) questionnaire. 
Results: The prevalence of ED in OSAS patients was 64,41%. Age and Diabetes constituted 
themselves as independent risk factors for more severe degrees of ED: OR=1,226 
(95%CI:1,062 – 1,415) and OR=31,205 (95%CI:1,222 – 796,557), respectively. Compared with 
nonsmokers, ex-smokers group revealed a positive association with ED: OR=4,32 (95%CI:1,09 
– 17,11). Hypertension and ACEI (angiotensin converting enzyme inhibitors) or ARB 
(angiotensin II receptor blockers) therapy were also correlated to ED symptoms: OR=3,25 
(95%CI:1,09-9,65) and 7,39 (95%CI:1,52-35,99), respectively. 
No association was found between BMI (p=0,254), alcoholic habits (p=0,357), acute 
myocardial infarction (p=0,315), dyslipidemia (p=0,239) and metabolic syndrome (p=0,215) 




Conclusions: The prevalence of ED in OSAS patients was 64,41%. ED determinants in our 
sample were age and diabetes. Past smoking habits, hypertension, ACEI/ARB therapy also 
revealed a statistically significant association. 
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Erectile dysfunction (ED) is defined as the consistent inability to obtain and/or 
maintain penile erection sufficient to permit satisfactory sexual intercourse, which has a 
negative impact on self esteem, quality of life, and interpersonal relationships of affected 
patients [1,2]. Its prevalence is estimated in 48% among Portuguese man aged 40 to 69 years 
old [3]. 
Obstructive sleep apnea syndrome (OSAS) is characterized by repetitive collapse of 
the upper airway due to the pharyngeal dilator muscles laxity [4], during sleep.   
Clinically, OSAS is defined by the presence of at least 5 obstructive respiratory events 
(apneas, hypopneas or respiratory effort related arousals) per hour of sleep in association 
with daytime sleepiness, loud snoring, witnessed breathing interruptions or awakenings due 
to gasping or choking [5]. The presence of 15 or more obstructive respiratory events in the 
absence of sleep related symptoms is also sufficient for the diagnosis [5]. OSAS affects an 
estimated 4% of men between the ages of 30 and 60 years [6], but it is believed that the 
proportion of clinically diagnosed OSAS is underestimated [7-9].  This is one of the most 
important medical conditions identified in the last 50 years [10], which is related to the 
elevated morbidity and mortality due to clinical complications as hypertension [11], 
congestive heart failure [12], acute myocardial infarction [13], stroke [14], diabetes [15], 
cognitive dysfunction [16] and depression [17]. 
In every REM sleep stage most men experience sleep related erections (SRE) [18], 
which are believed to be part of an intrinsic mechanism aimed to protect the morphological 
integrity of corpora cavernosa [19].  In OSAS, intermittent hypoxic events and sleep 
fragmentation restrain SRE, causing deleterious effects on erectile physiology [20-23].  
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Sleep dysfunction may also interfere on hypothalamic-pituitary axis as the usual 
REM-sleep testosterone increment is abolished in OSAS patients [24, 25]. Testosterone and 
luteinizing hormone (LH) nocturnal levels are decreased compared to normal controls [26], 
which are reversed by Continuous Positive Airway Pressure (CPAP) treatment [27]. 
Neural integrity may also be affected by the continuous sympathetic nervous system 
hyperactivity intrinsic to OSAS [28], opposing the physiological erectile mechanism [29]. A 
peripheral nerve dysfunction, whose presence and severity is related to the level of hypoxia, 
has also been described by bulbocavernous reflex latency tests [30-31].   
Repetitive hypoxic events induce oxidative stress, which is responsible for the 
decreased nitric oxide (NO) levels [32]. Endothelial dysfunction is also suggested by the 
increased endothelin levels [33]. This discrepancy between vasodilator and vasoconstrictor 
mediators impairs penile tumescence [34] contributing to erectile dysfunction in OSAS 
patients. CPAP treatment decreases the oxidative stress [35] and endothelin levels [36].  
Furthermore, a psychological component may be involved due to, for instance, 
depression [37] or fatigue excess [21].  
 ED could also be a direct consequence of hypertension and diabetes, common co-
morbidities in OSAS patients [22].  
Some inconsistencies have been found concerning prevalence data [19]. Thus, the 
main purpose of this study was to estimate the prevalence of ED in a population of OSAS 
patients sent to Hospital S. João for diagnosis and follow-up. Additionally, clinical and 






Between 28 September and 31 December 2010, all men admitted in sleep laboratory 
of Hospital de S. João Pulmonology Service for a first medical appointment because of a 
suspected OSAS, were invited to participate in the study. Every patient received an Informed 
Consent, IIEF-5 questionnaire and written form with information about the study, which they 
should deliver fulfilled thereafter. 
Information about BMI, previous medical history (diabetes, hypertension, stroke, 
acute myocardial infarction) and usual pharmacological therapy was obtained from medical 
files. 
We excluded patients without OSAS diagnostic confirmation and patients with ED 
already diagnosed. 
This study was approved by Ethics Commission from Hospital de S. João.  
 
IIEF -5 (International Index Erectile dysfunction - 5 item version) 
IIEF-5 is a simple and useful questionnaire to screen patients with ED [38]. Designed 
as a simplified version of IIEF, it is composed by 5 questions regarding erectile function and 
satisfaction [39] (annex 1).   Intervals 22 to 25, 17 to 21, 12 to 16, 8 to 11 and 5 to 7 points 
represent, respectively, ED absent, mild ED, mild to moderate ED, moderate ED and severe 





Polygraphic cardiorespiratory sleep study (PCSS) 
Polysomnography is routinely indicated for the diagnosis of sleep related breathing 
disorders [5, 41-45], but its use is limited by economical costs and waiting lists [46].  
PCSS is an alternative to the Polysomnography in the presence of an elevated pre-test 
probability [5]. A portable monitor with channels (at least 4) [47] is used, recording oro-nasal 
airflow, oxygen saturation, cardiac frequency, upper limb, abdominal and thoracic 
movements, body position and loud snoring [48]. 
All participants underwent PCSS with ApneaLink®, AlphaScreen Pro®, EMBLETTA® or 
Stardust® devices. We used variables as Apnea-hypopnea index (AHI), desaturation index 
(DI), minimum and medium oxygen saturation to assess OSAS severity. 
Mild, moderate and severe OSAS are defined, respectively, by an AHI 5-15; AHI >15 e 
<30 e AHI ≥ 30, according to established criteria [5]. 
 
Statistical analysis  
SPSS® (Statistical Package for Social Sciences), 18.0 version, was the software used to 
analyze statistical data.  
A frequency analysis was made to describe the population. Then Chi-Square test was 
used to determine the association between categorical variables and Kruskall wallis test to 
define any association between continuous and categorical variables. Multivariate logistic 
regression was used to evaluate the effect of each variable adjusted to other possible 
confounding factors.  





The general characteristics of the population are described in table 1. The mean age 
was 52 years. In 62 patients, 28 (45,1%) were obese, 23 (37,1%) had dyslipidemia, 11 (17,7%) 
metabolic syndrome (MS), 36 (58,1%) arterial hypertension, 10 (16,1%) diabetes and 4 
(6,5%) cardiac failure. Previous acute myocardial infarction, stroke and pelvic surgery were 
identified in 2 (3,2%), 6 (9,7%) and 2 (3,2%) participants, respectively. It was diagnosed mild 
OSAS in 30 (48,4%), moderate OSAS in 14 (22,6%) and severe OSAS in 17 (27,4%) individuals. 
The ED prevalence was 64,41%, being mild in 24 (38,7%), mild to moderate in 11 (17,7%), 
moderate in 2 (3,2%) and severe in 3 (4,8%) participants. 
Univariate analysis results are expressed in table 2. Aging was significant and directly 
related to the presence of ED: OR (CI 95%) of 3,90 (1,00 – 15,28); 5,50 (1,16 – 26,14); and 
6,00 (1,00 – 35,91) in age groups 46-55, 56-65 and >65 years, respectively. Past smoking 
habits also showed association with ED (OR 4,32 (1,09 – 17,11). Hypertension and ACEI 
(Angiotensin Converting Enzyme Inhibitors) or ARB (Angiotensin II Receptor Blockers) 
therapy revealed a statistically significant association with ED (OR 3,25 (1,09-9,65) and 7,39 
(1,52-35,99)).  
No association was found between dyslipidemia (p=0,239), metabolic syndrome 
(p=0,215), chronic therapy with beta blockers (p=0,217), calcium antagonists (p=0,827) and 
serotonin-selective reuptake inhibitors (p=0,250).  
All patients with diabetes, stroke, cardiac failure and previous pelvic surgery referred 
ED on questionnaire, so it was not possible to calculate odds ratio (OR) for these variables.  
PCSS parameter analysis is described in table 3.  Although not statistically significant, 
a trend of association was verified between ED and OSAS severity, measured by DI, 
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minimum and medium oxygen saturation and AHI (p=0,494, p=0,657, p=0,498 e p=0,403, 
respectively). 
Multivariate analysis is expressed on table 4. Age and diabetes were independent risk 
factors for more severe degrees of ED: OR (CI 95%) of 1,226 (1,062 – 1,415) and 31,205 
(1,222 – 796,557), respectively.  BMI (p=932), smoking habits (p=853), alcohol consumption 
(p=0,683), hypertension (p=0,077) and OSAS (p=0,661) did not provide evidence to be 





In 1981, Schmidt and Wise were the first to describe a relationship between ED and 
sleep disorders [49]. Thereafter, several studies confirmed the elevated prevalence of ED in 
OSAS patients [52-55]: Guilleminault et al reported ejaculatory dysfunction and decreased 
libido in 48% men with OSAS [50]; Hirshkowitz et al. verified that 91,3% patients with ED 
symptoms had also OSAS [51]; Seftel et al. concluded that 40% OSAS patients had ED [52]. 
However, this association is denied by Schiavi RC et al. [53]. In the present study, it was 
found a 64,41% ED prevalence, supporting most publications. 
Margel D et al. concluded that ED is associated with severe OSAS [54]. Therefore, 
despite the absence of statistical significance it was verified that patients who reported 
severe ED obtained the worst results in PCSS study (Table 3).   
Age, in the present study, proved to be an independent risk factor for ED, similar to 
what is suggested by the literature [55]. It was also confirmed that ED risk increases with 
aging.  It is established that age has more impact on erectile function than OSAS severity 
[56], as we could also find. 
Furthermore, the present data confirmed that Diabetes is an independent risk factor 
for ED. It was verified that diabetic patients have a risk 31 times superior to more severe 
degrees of ED, which is supported by the effect of endothelial dysfunction on erectile tissue 
structure [57].  
Arterial hypertension was associated with ED in the univariate analysis. However, an 
association with more severe ED degrees was not confirmed within multivariate analysis. 
This difference is probably due to a confounding effect of diabetes, suggested by the fact 
that 9 out of 10 diabetic patients also described hypertension.  
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An association between MS and ED was not found. Nevertheless, it is possible that 
the used classification have underestimated the real proportion of affected patients since it 
was based on the patient report and did not include triglycerides or cholesterol plasmatic 
measurements [58]. Similarly, this study did not prove an association between BMI and ED, 
with patients in BMI interval 25-29 reporting more symptoms than those included in 
superior BMI categories. This is probably related to the fact that the BMI interval 25-29 
included older patients (43% patients between 56 and 65 years and 50% of patients older 
than 65 years), compared to the other categories (data not shown in tables). It is possible to 
conclude that, in our sample, aging is an important confounding when analyzing BMI data.  
As a marker of systemic endothelial dysfunction, dyslipidemia may be more prevalent 
in ED patients [59]. Fibrats and Statins, lipid-lowering drugs, can also provoke ED as a side 
effect [60]. These consequences were not observed in our sample maybe due to a recall 
bias.                
Concerning smoking habits, only ex-smokers showed a statistically significant 
association with ED, eventually due to the fact that this group reported heavier smoke loads 
(34 pack-years), compared to current smokers (25 pack-years). In a recent cross-sectional 
study [61] smoking careers of more than 23 years or 20 cigarettes per day were significantly 
associated with ED.  
Regarding chronic medication, an association was found between ACEI/ARA and ED. 
Actually, anti-hypertensive therapy is associated with adverse sexual effects, most 
commonly involving diuretics and beta-blockers [62]. ACEI/ARA were the most frequently 
used drugs and its association with ED may be due to hypertension itself. Beta-blockers were 
used only by 4 patients, explaining the absence of a statistical significant association with ED.    
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This study has some advantages. Patients with co-morbidities were not excluded, 
allowing measuring their impact on erectile function. The effect of chronic medication was 
also evaluated.   
Though, this investigation has some limitations. The sample size is smaller compared 
to other studies due to a high refusal rate in patients’ participation, possibly related to the 
embarrassment in describing such private subject. In contrast with other studies [55], the 
protocol did not include testosterone measurements so the ED was exclusively assessed by a 
questionnaire. 
For future work it is suggested that larger scale studies be conducted and performed 
and also multidisciplinary approach is crucial to OSAS patients as this is a syndrome with 






The ED prevalence was 64,41%. 
ED determinants were age and diabetes, which constituted themselves as 
independent risk factors for more severe degrees of ED. Past smoking habits, hypertension 
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Table 1: Population general description (n= 62) 
 Variables Frequencies 
Age 
 Mean (years) 
 ≤ 45 
46-55 
56-65 
>65   
52,16 
20 (32,3 %) 
18 (29 %) 
14 (22 %) 








11 (17,7 %) 
23 (37,1 %) 
19 (30,6 %) 




   Smoke load (mean) 
 Past 















   
Table 1: Population general description (cont.) 







































BMI (body mass índex); OSAS (obstructive sleep apnea 
syndrome); ED (Erectile dysfunction) classification: absent 
(IIEF-5 22-25); mild (IIEF-5 17-21); mild to moderate (IIEF-5 
12-16); moderate (IIEF-5 8-11); DE severe (IIEF-5 5-7). 
Table 2: ED prevalence and association with clinical and demographic 
variables 











3,90 (1,00 – 15,28) 
5,50 (1,16 – 26,14) 












2,06 (0,42 - 9,97) 
0,64 (0,14 – 2,91) 
0,71 (0,12 – 4,32) 
0,254 







0,50 (0,14 – 1,82) 



















Table 2: ED prevalence and association with clinical and demographic 
variables (cont.) 






















0,84 (0,26 – 2,70) 











4,32 (1,09 – 17,11) 















7,39 (1,52-35,99) 0,007 







Table 3: PCSS study parameter analysis according to ED severity  
ED DI MinO2Sat MedO2Sat AHI 
Absent 
Median 13,3 81,0 94,6 16,3 
Min-Max 1,8 – 85,0 63,0 – 94,0 91,0 – 96,7 8,2 – 48,8 
Mild 
Median 7,75 83,0 95,0 13,6 
Min-Max 0,6 – 70,0 24,0 – 91,0 88,0 – 98,0 5,3 – 76,0 
Mild to 
moderate 
Median 13,20 82,0 94,0 30,0 
Min-Max 1,4 – 67,2 22,0 – 92,0 77,0 – 97,0 6,3 – 91,0 
Severe 
Median 24,0 76,0 89,0 24,9 
Min-Max 9,0 – 81,3 50,0 – 84,0 84,4 – 96,4 9,9 – 83,2 
p 0,494 0,657 0,498 0,403 
It was not possible to analyze the category “moderate DE” because it was composed 
only by one subject   
ED (Erectile dysfunction) classification: absent (IIEF-5 22-25); mild (IIEF-5 17-21); mild 
to moderate (IIEF-5 12-16); moderate (IIEF-5 8-11); DE severe (IIEF-5 5-7). 
DI (desaturation index); MinO2Sat (minimum O2 saturation);  MedO2Sat (medium O2 








Table 4: Multivariate logistic regression# on the association 
between some clinical variables and ED 
Variable p OR CI 95%* 
Age 0,005 1,226 1,062 – 1,415 
BMI 0,932 0,989 0,759 – 1,287 
Smoking habits 





0,293 – 4,407 
 
Alcohol 
consumption        
0,683 0,994 0,964 – 1,024 
Diabetes 0,037 31,205 1,222 – 796,557 
Hypertension 0,077 10,453 0,776 – 140,760 
OSAS 0,661 1,580 0,204 – 12,233 
# Dependent variable was categorized as “absent and mild ED” 
and “mild to moderate to severe ED” 
* 95% confidence interval 










Annex 1 – IIEF-5 Questionnaire 
How do you rate your confidence that you could get and keep an erection 




5) Very high 
 
When you had erections with sexual stimulation, how often were your erections hard 
enough for penetration? 
 
1) Never/almost never 
2) Rarely (much less than half the time) 
3) Occasionally (about half the time) 
4) Most of time (much more than half the time) 
5) Almost always/always 
During sexual intercourse how often were you able to maintain an erection after 
penetration? 
 
1) Never/almost never 
2) Rarely (much less than half the time) 
3) Occasionally (about half the time) 
4) Most of time (much more than half the time) 
5) Almost always/always 
 
During sexual intercourse, how difficult has it been to maintain your erection until 
completion of intercourse? 
1) Extremely difficult 
2) Very difficult 
3) Difficult 
4) Slightly difficult 
5) Not difficult 
 
When you attempted sexual intercourse, how often was it satisfactory to you? 
1) Never/almost never 
2) Rarely (much less than half the time) 
3) Occasionally (about half the time) 
4) Most of time (much more than half the time) 
5) Almost always/always 
 
